Similar articles for PMID: 30642824

Year	Number of Results
2013	1
2014	2
2015	5
2016	7
2017	25
2018	45
2019	56
2020	27
2021	8
2022	4
2024	0

1

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

Esfahani K, Meti N, Miller WH Jr, Hudson M. Esfahani K, et al. CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870. CMAJ. 2019. PMID: 30642824 Free PMC article. Review. No abstract available.

2

Atypical autoimmune adverse effects with checkpoint blockade therapies.

Friedman CF, Snyder A. Friedman CF, et al. Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658. Ann Oncol. 2017. PMID: 27993802 Free article. No abstract available.

3

Immune checkpoint inhibitors.

Hui E. Hui E. J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13. J Cell Biol. 2019. PMID: 30760493 Free PMC article. Review.

4

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.

Rambhia PH, Reichert B, Scott JF, Feneran AN, Kazakov JA, Honda K, Koon H, Gerstenblith MR. Rambhia PH, et al. Int J Clin Oncol. 2019 Oct;24(10):1171-1181. doi: 10.1007/s10147-019-01490-2. Epub 2019 Jul 18. Int J Clin Oncol. 2019. PMID: 31321613 Review.

5

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.

Bazhin AV, Amedei A, Karakhanova S. Bazhin AV, et al. Front Immunol. 2018 Dec 5;9:2878. doi: 10.3389/fimmu.2018.02878. eCollection 2018. Front Immunol. 2018. PMID: 30568661 Free PMC article. No abstract available.

6

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Khoja L, et al. Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286. Ann Oncol. 2017. PMID: 28945858 Free article. Review.

7

Efficacy and safety of immune checkpoint blockade for brain metastases.

Harary M, Reardon DA, Iorgulescu JB. Harary M, et al. CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11. CNS Oncol. 2019. PMID: 30854898 Free PMC article. No abstract available.

8

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S. Inno A, et al. Tumori. 2017 Sep 18;103(5):405-421. doi: 10.5301/tj.5000625. Epub 2017 May 10. Tumori. 2017. PMID: 28497847 Review.

9

Checkpoint inhibitor immunotherapy in kidney cancer.

Xu W, Atkins MB, McDermott DF. Xu W, et al. Nat Rev Urol. 2020 Mar;17(3):137-150. doi: 10.1038/s41585-020-0282-3. Epub 2020 Feb 4. Nat Rev Urol. 2020. PMID: 32020040 Review.

10

New checkpoint inhibitors ride the immunotherapy tsunami.

Mullard A. Mullard A. Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066. Nat Rev Drug Discov. 2013. PMID: 23812256 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

166 results

Results by year